560 related articles for article (PubMed ID: 16641889)
1. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
Franca R; Spadari S; Maga G
Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
[TBL] [Abstract][Full Text] [Related]
2. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.
Zheng YH; Irwin D; Kurosu T; Tokunaga K; Sata T; Peterlin BM
J Virol; 2004 Jun; 78(11):6073-6. PubMed ID: 15141007
[TBL] [Abstract][Full Text] [Related]
3. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.
Sawyer SL; Emerman M; Malik HS
PLoS Biol; 2004 Sep; 2(9):E275. PubMed ID: 15269786
[TBL] [Abstract][Full Text] [Related]
4. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
Holmes RK; Koning FA; Bishop KN; Malim MH
J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
[TBL] [Abstract][Full Text] [Related]
5. [The innate antiretroviral defense of human cells, based on the DNA editing].
Pupecka M; Pacak A
Postepy Biochem; 2006; 52(3):247-52. PubMed ID: 17201059
[TBL] [Abstract][Full Text] [Related]
6. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex.
Shirakawa K; Takaori-Kondo A; Kobayashi M; Tomonaga M; Izumi T; Fukunaga K; Sasada A; Abudu A; Miyauchi Y; Akari H; Iwai K; Uchiyama T
Virology; 2006 Jan; 344(2):263-6. PubMed ID: 16303161
[TBL] [Abstract][Full Text] [Related]
8. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA; Pathak VK
J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
[TBL] [Abstract][Full Text] [Related]
9. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
10. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.
Peng G; Lei KJ; Jin W; Greenwell-Wild T; Wahl SM
J Exp Med; 2006 Jan; 203(1):41-6. PubMed ID: 16418394
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.
Santa-Marta M; Aires da Silva F; Fonseca AM; Rato S; Goncalves J
Mol Immunol; 2007 Jan; 44(4):583-90. PubMed ID: 16580072
[TBL] [Abstract][Full Text] [Related]
12. Death by deamination: a novel host restriction system for HIV-1.
Goff SP
Cell; 2003 Aug; 114(3):281-3. PubMed ID: 12914693
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
Opi S; Kao S; Goila-Gaur R; Khan MA; Miyagi E; Takeuchi H; Strebel K
J Virol; 2007 Aug; 81(15):8236-46. PubMed ID: 17522211
[TBL] [Abstract][Full Text] [Related]
14. Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.
Albin JS; Brown WL; Harris RS
Virology; 2014 Feb; 450-451():49-54. PubMed ID: 24503066
[TBL] [Abstract][Full Text] [Related]
15. APOBEC-mediated viral restriction: not simply editing?
Holmes RK; Malim MH; Bishop KN
Trends Biochem Sci; 2007 Mar; 32(3):118-28. PubMed ID: 17303427
[TBL] [Abstract][Full Text] [Related]
16. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
[TBL] [Abstract][Full Text] [Related]
17. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
18. Further investigation of simian immunodeficiency virus Vif function in human cells.
Gaddis NC; Sheehy AM; Ahmad KM; Swanson CM; Bishop KN; Beer BE; Marx PA; Gao F; Bibollet-Ruche F; Hahn BH; Malim MH
J Virol; 2004 Nov; 78(21):12041-6. PubMed ID: 15479843
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Vif and APOBEC3G: multiple roads to one goal.
Goncalves J; Santa-Marta M
Retrovirology; 2004 Sep; 1():28. PubMed ID: 15383144
[TBL] [Abstract][Full Text] [Related]
20. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.
Pace C; Keller J; Nolan D; James I; Gaudieri S; Moore C; Mallal S
J Virol; 2006 Sep; 80(18):9259-69. PubMed ID: 16940537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
